(+)-Apogossypol 10mg

您好！欢迎来到炼石商城请登录注册兼职小伙伴

我的购物车

Qiagen 凯杰 Biosharp Omega

客服热线 0771-3293894

首页酶、辅酶及抑制剂MCE>

图片仅供参考，请以实物为准

市场价：: 5000.00

促销价：: ¥5000.00

货号：HY-13408

品牌：MCE

配送至：

北京朝阳

支付：账期货到付款

数量：

支 (预计4-5工作日到货(以MCE官网货期为准))

工作时间

周一至周五：9:00-18:00

咨询电话

0771-3293894

在线咨询

: 客服郭恒蔡玉坤曾宪飞技术咨询

浏览了该商品的用户最终购买

RNeasy Mini Kit (50) 50次

3720.00

Plasmid Mini Kit I(200) 200...

576.00

10ul吸头，透明，袋装，可灭菌...

85.80

浏览了该商品的用户还浏览了

QIAfilter Plasmid Maxi Kit (...

3000.00

QIAamp DNA Blood Midi Kit (2...

2680.00

QIAamp UCP Pathogen Mini Kit...

4112.00

商品介绍
商品咨询

(+)-Apogossypol 是一种泛 BCL-2 拮抗剂，与 Mcl-1, Bcl-2 和 Bcl-xL 结合， EC₅₀ 分别为 2.6，2.8 和 3.69 μM。

Description

(+)-Apogossypol is a pan-BCL-2 antagonist. (+)-Apogossypol binds to Mcl-1, Bcl-2 and Bcl-xL with EC₅₀s of 2.6, 2.8 and 3.69 µM, respectively.

IC₅₀ & Target^[1]

Mcl-1

2.6 μM (EC₅₀)

Bcl-2

2.8 μM (EC₅₀)

Bcl-xL

3.69 μM (EC₅₀)

In Vitro

In agreement with NMR binding and fluorescence polarization assays (FPAs) data, (+)-Apogossypol displays potent binding affinity to Bcl-xL with K_d values of 1.7 µM^[1].To investigate the inhibitory effects of (+)-Apogossypol and Gossypol on LNCaP cell survival, the MTT assay is performed. The results demonstrate that (+)-Apogossypol inhibits the proliferation of LNCaP cells in a time- and dose-dependent manner, in a similar way with Gossypol. The concentration for 50% inhibition (IC₅₀) on LNCaP cells within ~72 h is 9.57 μM, while the IC₅₀ of Gossypol on LNCaP cells is 10.35 μM^[2].

In Vivo

Due to its modified structure, (+)-Apogossypol is expected to exhibit lower toxicity while maintaining the significant anti-growth and anti-tumor activities in vitro, similar to those of Gossypol. The anti-cancer effect of (+)-Apogossypol is evaluated in mice bearing subcutaneous LNCaP cell xenografts. The tumor growth is monitored and measured by a caliper and balance. The survival rate of the mice is notably improved by (+)-Apogossypol. Of note, the tumor sizes are also markedly decreased by (+)-Apogossypol treatment (P<0.01)^[2].

Solvent & Solubility

In Vitro:

10 mM in DMSO

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0218 mL	10.1092 mL	20.2184 mL
5 mM	0.4044 mL	2.0218 mL	4.0437 mL
10 mM	0.2022 mL	1.0109 mL	2.0218 mL

* Please refer to the solubility information to select the appropriate solvent.

References

[1]. Wei J, et al. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2009 Apr;8(4):904-13.

[2]. Zhan W, et al. Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivo. Mol Med Rep. 2015 Jun;11(6):4142-8.

Cell Assay ^[2]	The cytotoxic effect of (+)-Apogossypol and Gossypol on prostate cancer cell lines is measured by the MTT assay. LNCaP cells are seeded onto sterile 96 well flat bottomed plates and incubated overnight. Then diluted (+)-Apogossypol (1 and 10 μM) and Gossypol are added into each well with gradient concentrations (2-20 μM). For the cell viability test, tumor cells are suspended in a mixed solution of 200 μL complete medium and 0.2 μL DMSO, and wells with 200 μL complete medium are used as blank controls. The plates are incubated at 37°C with 5% CO₂ for 72 h. The medium is then removed, and 0.5 μM MTT is added into the wells. After another 4 h, 150 μL DMSO is added into each well. The absorbance is read at 570 nm on a microplate reader. The drug concentration yielding 50% cell inhibition (IC₅₀) is determined. All experiments are performed in triplicate^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Mice^[2] Female athymic nude (nu/nu) mice (4-6 weeks of age, weighing 20-25 g) are used. LNCaP cells (2×10⁶) are injected subcutaneously into each mouse. The tumor volume is measured every two days using a caliper and calculated. When subcutaneous tumor sizes reach 150-200 mm³, these mice are randomly divided into three groups, each group consisting of 10 mice. Next, they are treated with (+)-Apogossypol and Gossypol, respectively, at 20 mg/kg intraperitoneally, q.d. every 7 d for 28 d. The vehicle control group receive the same amount of DMSO as in the treatment groups. The tumor volume is detected every day. The tumor tissues are fixed in 10% formalin solution. The tissues are embedded with paraffin, and the sections are prepared. Samples are stained with hematoxylin and eosin and microscopically examined. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Wei J, et al. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2009 Apr;8(4):904-13. [2]. Zhan W, et al. Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivo. Mol Med Rep. 2015 Jun;11(6):4142-8.

Molecular Weight	494.60
Formula	C₂₈H₃₀O₆S
CAS No.	66389-74-0
SMILES	OC1=C2C=C(O)C(O)=C(C(C)C)C2=CC(C)=[C@]1[C@]3=C(C)C=C4C(C(C)C)=C(O)C(O)=CC4=C3O.[S]
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping	Room temperature in continental US; may vary elsewhere